Danaher (DHR) Expected to Announce Earnings on Wednesday

Danaher (NYSE:DHR) is anticipated to announce its earnings results before the market opens on Wednesday, January 29th. Analysts expect Danaher to post earnings of $2.14 per share and revenue of $6,384,506.38 billion for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Danaher Price Performance

Shares of DHR opened at $250.51 on Tuesday. The firm has a fifty day simple moving average of $235.33 and a two-hundred day simple moving average of $253.62. The firm has a market cap of $180.94 billion, a PE ratio of 47.81, a P/E/G ratio of 4.43 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher has a 1-year low of $225.42 and a 1-year high of $281.70.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Analysts Set New Price Targets

Several brokerages have recently weighed in on DHR. Guggenheim began coverage on shares of Danaher in a research note on Thursday, December 19th. They issued a “buy” rating and a $275.00 price objective on the stock. TD Cowen boosted their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Royal Bank of Canada cut their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Finally, Barclays decreased their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.